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Abstract
Background: The prevalence of blindness and visual impairment from glaucoma is influenced by the criteria used
to define these entities, which differ between countries and regions, as well as among published reports. The
objective of the present study was to ascertain the extent to which different criteria of blindness and visual
impairment influence estimates of the number of patients classified as blind or visually impaired by glaucoma in a
clinic-based population.
Methods: We conducted a retrospective chart review of 914 patients with open-angle glaucoma to compare numbers
of patients identified as visually impaired with and without considering visual field status. We also compared
proportions classified using World Health Organisation (WHO) and United States (US) blindness criteria, and applying a
new US Social Security Administration (SSA) disability criterion: perimetric mean deviation (MD) ≤ -22 dB.
Results: Forty patients (4.4%) were bilaterally blind from glaucoma by the WHO criteria. Fifty-two (5.7%) were blind
by the the US criterion. Assessing only visual acuity, 14 (1.5%) patients were blind by the WHO criteria and 24
(2.6%) by the US definition. Eighty-five (9.3%) met the US SSA disability criterion. Among those, 52 were impaired
also by the WHO definition. No patients impaired according to the WHO criteria had MD values better than -22 dB.
Conclusions: Excluding visual field status will seriously underestimate the prevalence of glaucoma blindness. In our
patient population, 30% more patients were classified as blind by the US than by the WHO definition. Also, 60%
more were identified as visually impaired by the US SSA criterion than by the WHO criteria. Visual field assessment
is vital to determine visual impairment caused by glaucoma.
Background
Open-angle glaucoma is the second most common cause
of blindness globally [1]. It is important that we have
knowledge about the prevalence of visual impairment
caused by glaucoma in order to enable correct allocation
of resources for glaucoma care, and also to allow evalua-
tion of the effects of treatment and potential benefits of
population screening.
Evaluation of the prevalence of blindness and visual
impairment from glaucoma is influenced by the criteria
used to define these entities, which differ between coun-
tries and regions. The definition of visual impairment sti-
pulated by the World Health Organisation (WHO) can be
considered the current gold standard in this context. How-
ever, many countries use their own criteria for blindness.
An example of this is the definition used in the United
States here designated the US criteria, which is also widely
accepted and used in other countries. The number of peo-
ple identified as blind from glaucoma should be higher
when using the US definition than with the WHO defini-
tion, since the latter includes stricter criteria for blindness
both by visual acuity (VA) and visual field loss.
In some cases, the prevalence of visual impairment
(blindness and low vision) in glaucoma is studied and
reported based on VA alone, i.e., not including visual field
status [2-21]. It seems obvious that this approach will yield
falsely low estimates of the prevalence, because visual
impairment will not be recognised in patients who have
end-stage glaucomatous visual field loss with preserved
central VA.
The US Social Security Administration (SSA) recently
endorsed use of a new criterion for disability determina-
tions, the perimetric mean deviation (MD). This ruling
[22] states that an MD of -22 dB on a 30-2 Humphrey
threshold visual field corresponds approximately to a
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any medium, provided the original work is properly cited.constriction of the visual field to less than 20° of fixation,
and recommends an MD of ≤ -22 dB as a visual field cri-
terion to define disability.
The objective of the present study was to ascertain the
extent to which different criteria of blindness and visual
impairment influence estimates of the number of patients
classified as blind or visually impaired by glaucoma. Our
primary aim was to investigate how omitting visual field
status from criteria affects the rate of visual impairment.
We also wanted to compare the number of patients identi-
fied as blind from glaucoma by the US and the WHO
glaucoma blindness definitions, respectively, and to esti-
mate the number classified as disabled by the US SSA
visual field criterion compared to the WHO criteria.
Methods
Patients
We performed a retrospective chart review of patients
diagnosed with open-angle glaucoma who visited the
Department of Ophthalmology at Malmö University Hos-
pital between 1 June 2004 and 31 May 2006. The great
majority of these patients had reproducible visual field
defects defined as a Glaucoma Hemifield Test “outside
normal limits” on a SITA Standard test performed on a
Humphrey Field Analyzer (HFA; Carl Zeiss Meditec Inc.,
Dublin, CA, USA), compatible with glaucoma, and not
explained by other ocular or neurological disorders.
We selected patients born on days 1-15 of each month
and used a study period of 2 years so that we would not
miss those who made only infrequent visits to the Malmö
Department of Ophthalmology. Glaucoma patients not
treated primarily at this department (e.g., those referred
for cataract surgery, laser treatment, or a second opinion)
were not eligible, because our records on such cases con-
tained insufficient data for reliable classifications.
For each patient, we recorded VA, perimetric findings in
both eyes (as MD values of SITA Standard 30-2 tests in
the great majority of cases, but also by Goldmann kinetic
perimetry in a few), age, and presence/absence of visual
impairment determined by the various criteria studied.
Patients who met the WHO blindness criterion for VA
and lacked visual field data were assigned an MD value of
-30 dB.
The study was approved by the Regional Ethics Board
in Lund, Sweden, and the tenets of the Declaration of
Helsinki were followed.
Comparisons of criteria
The term visual impairment includes both low vision
and blindness. Here, bilateral visual impairment was
based on best-corrected VA and/or visual field status in
the best eye, and hence a person with one blind eye and
low vision in the other was considered to have low
vision.
Each patient was evaluated for the presence of visual
impairment using these different criteria:
1. Low vision and blindness according to the WHO
criteria
2. Blindness according to the US criteria
3. Impairment according to the perimetric MD value
criterion suggested by the US SSA [22] (Table 1)
4. Low vision and blindness based on VA alone, thus
omitting visual field data
Visual field status is not included in the US criterion,
defining low vision as VA < 0.5. Therefore, we chose
not to register patients classified as having low vision
according to this criterion.
We calculated the diameter of the remaining visual
field as recommended by the SSA [23]. Pseudoisopters
w e r ed r a w no nt h eH F An u m e r i c a lt h r e s h o l dd Bp r i n t -
outs, midway between test point locations with thresh-
old sensitivity values of 10 dB or better, and points with
sensitivity less than 10 dB (Figure 1).
The causes of visual loss were determined for all patients
with visual impairment. For each impaired eye, the disease
that initially contributed to visual loss was noted as the
leading cause. However, if the time for impairment could
not be established, the disease that was deemed to contri-
bute most to the impairment was registered as the main
cause. Visual field data were available in most cases in
which glaucoma was deemed to be the main cause. Such
data were lacking in some cases, such as for elderly
patients with end-stage glaucoma who could not partici-
pate in visual field testing, or when VA was so low that
visual field testing had been abandoned. Classification in
those cases was based solely on VA.
We used both the WHO criteria and the US criterion
(blindness only) to determine the number of bilaterally
blind/visually impaired patients, and we calculated the
effect of omitting visual field status from the definition of
visual impairment. We also investigated the difference in
the numbers of patients defined as blind by the WHO
and US criteria. The numbers of patients classified as
impaired with WHO criteria and the US SSA visual field
criterion were compared.
Statistical analyses
We applied descriptive statistics to compare the US and
WHO criteria regarding the number of patients identified
as blind and visually impaired, and the number of
patients with and without using visual field data. The
number classified as blind and visually impaired will
always be larger when visual field criteria are applied
than when they are omitted, because all patients who are
blind according to VA criteria alone are also blind when
field data are included. Similarly, all patients who are
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blind according to the less stricter US criteria. Analyses
of numbers of blind according to WHO and US criteria
and with and without taking visual fields into account
were, therefore, purely descriptive, and no analyses for
significances were performed.
Results
A total of 914 eligible patients were evaluated. Their
mean age was 79 years (range 30-100 years). Nearly all
the patients were Caucasians.
Table 2 presents the total numbers of patients identified
as blind or visually impaired by the WHO and US criteria
with and without taking visual field status into account.
The number of blind patients was 30% higher according
to the US criteria than the WHO criteria. Using the WHO
criteria, the number of patients classified as blind was 40
when visual field was included but only 14 when visual
field status was omitted, which represents a 65% reduction
(Figure 2). Similarly, the WHO criteria identified visual
impairment in only 37 patients when visual field status
was ignored as compared to 58 patients when field status
was included, a 36% reduction. Using the US criterion, the
number of blind patients was only 24 when visual fields
w e r eo m i t t e dc o m p a r e dt o5 2w h e nf i e l ds t a t u sw a s
included, a reduction of 54%.
Eighty-five patients (9.3%) met the SSA criterion of bilat-
eral visual impairment caused by glaucoma in both eyes
with measured or assigned MD values ≤ -22 dB. Among
those, 52 were visually impaired also by the WHO defini-
tion. No patients who were impaired according to the
WHO criteria had MD values better than -22 dB.
Fifty-four patients had visual fields tested in one eye
only, and 36 had no field tests at all. In 54 (60%) of those
cases, the reason tests were not performed was that the
patients already had very low VA and totally cupped
discs at the initial visit, and in 28 cases it was because the
patients’ visual impairment was due to a cause other than
glaucoma. For nine patients, perimetric results were not
available for the study period or had been obtained only
by testing on the Competer perimeter. Three patients
were considered unable to do undergo perimetric testing.
Discussion
The most important finding of the current study is that a
very large proportion of the visually impaired glaucoma
patients were not identified as being visually impaired
when only VA criteria were used to define such low vision.
Table 1 Visual impairment criteria*
WHO US US SSA
Low
vision
VA < 0.3 (20/70) and/or a constriction of the central visual
field to < 20°
VA < 0.5 (20/40). MD ≤ -22 dB in
both eyes.
Blindness VA < 0.05 (20/400) and/or a constriction of the central
visual field to < 10°
VA ≤ 0.1 (6/60) and/or a constriction of the central
visual field to < 20°
*Visual impairment = low vision + blindness.
VA, visual acuity; MD, mean deviation; dB, decibel.
Figure 1 Calculation of the diameter of the remaining visual field. The central visual field is indicated by the pseudoisopter (red line). The
distance is 6° between each test point location and 3° between test points and the pseudoisopter. The pseudoisopter is used to calculate the
widest diameter of the remaining central visual field. This field is constricted to 18° around the point of fixation.
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Hattenhauer et al [24], in which the risk of bilateral blind-
ness was calculated for patients 20 years after a glaucoma
diagnosis had been made using the US definition of blind-
ness. Those authors found that the risk was 9% based on
both visual field status and VA together but was 5% when
based on VA alone, which is similar to our results. The
visual field data in the study by Hattenhauer and collea-
gues came mainly from kinetic Goldmann perimetry. The
Baltimore Eye Survey [25] using similar visual field testing,
on the other hand suggested that the number of patients
classified as having bilateral blindness would increase by at
most 25% when combining visual field data and VA com-
pared to if evaluation were based on VA alone. The visual
field criteria for blindness and for visual impairment are
quite restrictive. In glaucoma the remaining visual field is
seldom circular, and many eyes are not classified as blind
despite very small remaining field areas. A narrow seg-
ment of the field with test points with sensitivity values of
10 dB or better, that extends outside 10° from fixation
m a yb ee n o u g hf o ra ne y en o tt of u l f i l la n yo ft h et w o
blindness criteria (Figure 3). It is, therefore, obvious that
impairment caused by glaucomatous field loss requires
loss of a very considerable proportion of normal function
and has large consequences if bilateral, and that field loss
is a very important part of the visual burden caused by
glaucoma.
Our results indicate that it is very likely that glaucoma
impairment and blindness have been considerably under-
estimated in papers reporting rates of blindness deter-
mined using VA data, but omitting visual field status
[3,4,15,18]. Furthermore, glaucoma must have been sub-
stantially underestimated as a cause of blindness in
numerous population studies which have relied solely on
VA [2,5-14,16,17,19-21]. Relying on visual acuity alone
results in under-estimation of impairment caused by
other disease, e.g., in onchocerciasis [26].
The number of patients classified as blind from glau-
coma differs between investigations using the US criteria
and those applying the WHO criteria. To our knowledge
only two studies including visual field status has used both
the WHO and the US definition to evaluate glaucoma
blindness [27,28]. However, very few patients in the cited
investigations were blind from glaucoma, and thus the
results of that evaluation do not allow any conclusions to
be drawn about the difference in the numbers of blind
identified using these two approaches.
We found it interesting to study results obtained using
the US SSA criteria for visual impairment. To our knowl-
edge no other investigators have published visual impair-
ment data based on MD values. It would no doubt be
easier to use this MD-based criterion in surveys compar-
ing visual impairment than performing actual measure-
ments of visual field constriction, and that would also
facilitate comparison of observations made in different
studies.
This study had several strengths. Automated HFA peri-
metry is standard practice in our clinical setting, and
other types of perimetry are rarely used. Ophthalmic
practice in Sweden is somewhat unusual in that glau-
coma care is delivered predominantly by the public
health services. Our hospital provides primary glaucoma
care for approximately three quarters of all patients with
this disease in the catchment area. The current study was
Table 2 Influence of visual field status on the number of
patients classified as blind/visually impaired from
glaucoma
Visual fields + VA*
No. (% of all patients)
VA alone
No. (%)
WHO - blindness 40 (4.4%) 14 (1.5%)
WHO - visual impairment 58 (6.3%) 37 (4.0%)
US - blindness 52 (5.7%) 24 (2.6%)
* VA, visual acuity.
Figure 2 Blindness by visual acuity or field. Number of blind
patients (best eye) using visual acuity (VA) or visual field (VF) data
with WHO and US criteria.
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number of visually impaired patients. Therefore, our
results should be reasonably representative of clinic-
based populations. One may speculate on whether the
proportions of individuals classified as blind from glau-
coma using visual acuity alone or taking both visual
acuity and fields into account are the same in clinic-
based cohorts and in the population. If so the true preva-
lences of glaucoma blindness could be more than twice
as large as those reported from many countries, and a
“correction/multiplication factor” of 2.2 (US) or 2.9
(WHO) could be used to help provide at least a rough
estimate of the total number of blind glaucoma patients
in areas where such blindness has been estimated using
visual acuity alone. Similar multiplication factors have
been used by WHO to estimate low vision in areas where
only blindness and not low vision have been assessed
[29]. Reduced visual acuity seems to influence measur-
able reduction of quality of life earlier than field loss, and
measurable utility may not be affected until end stage
visual field status in the better eye [30,31]. It is, therefore,
even possible that the proportion of undiagnosed indivi-
duals with glaucoma in the population who are blind
according to visual field criteria, but not because of poor
visual acuity, are even more common in the population
than in clinic-based cohorts.
A relative weakness of our investigation is that it was
retrospective, and therefore some data were incomplete or
missing. However, missing data constitute a problem in
prospective studies as well. Visual field testing can also
pose a problem in very old patients or in elderly with very
low vision, who might have to be followed without such
testing during their last few years of life. Also, considering
prospective studies, some institutionalised patients are lost
to follow-up, and some continue to come for examinations
but no subjective measurements of visual function can be
performed. The great majority of our patients were sub-
jected to regular follow-up that included visual field test-
ing, and there was little occurrence of incomplete or
missing data.
Conclusions
In conclusion, we found that the number of patients
with bilateral blindness from glaucoma was greatly
underestimated when the evaluation was based solely on
VA testing. The number of bilaterally blind was consid-
erably higher when using the US definition of blindness
compared to the WHO definition. The number of
impaired patients was 60% higher by the US SSA
impairment criterion than by the WHO criteria. Visual
field testing is very important to achieve correct assess-
ment of visual impairment caused by glaucoma.
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